Who is sponsoring NCT00204230?

NCT00204230 is sponsored by University Hospital Muenster.

What drugs are being tested in NCT00204230?

Interventions in NCT00204230: mycophenolate mofetil (drug).

What condition does NCT00204230 study?

NCT00204230 studies Immunosuppressive Agents, Kidney Failure, Chronic, Kidney Transplantation.

Is NCT00204230 still recruiting?

NCT00204230 is currently terminated. Last updated 12 September 2005.

Last reviewed 2005-09-12 · How we verify

NCT00204230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Controlled Study: Effect of Mycophenolatmofetil in Patients With Histologically Proven Chronic Allograft Nephropathy

Terminated NA Last updated 12 September 2005

What this trial tests

NA trial testing mycophenolate mofetil (drug) in Immunosuppressive Agents in 86 participants. Terminated before completion.

Timeline

1 October 1999

1 September 2002

Quick facts

Lead sponsor	University Hospital Muenster
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	86
Start date	1 October 1999
Estimated completion	1 September 2002

Drugs / interventions tested

mycophenolate mofetil (drug) — full drug profile →

Conditions studied

Immunosuppressive Agents — all drugs for Immunosuppressive Agents →
Kidney Failure, Chronic — all drugs for Kidney Failure, Chronic →
Kidney Transplantation — all drugs for Kidney Transplantation →

Sponsor

University Hospital Muenster

Who can join

Adults 18 to 70, any sex, with Immunosuppressive Agents or Kidney Failure, Chronic. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

course of renal function over 35 weeks

Sponsor's own description

Prospective, randomised study: Effect of mycophenolatmofetil (MMF) and CNI withdrawal in patients with histologically proven chronic allograft nephropathy Indication: change in immunosuppressive treatment of chronic allograft nephropathy (CAN)after renal transplantation Hypothesis: Antimetabolite MMF is able to stop progression of CAN and improve blood pressure/ metabolic parameters and structural vessel wall changes Primary Target:effects of CNI withdrawal and MMF on renal function: stabilisation and/or improvement Secondary Targets: Incidence of adverse events Evaluation of the calcineurin inhibitor free MMF treatment effects on blood pressure, lipids, glucose metabolism and on structural and functional vesselwallchanges Method:open prospective, randomized two-tailed, monocentric study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Immunosuppressive Agents

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting

Other University Hospital Muenster trials

Trials by the same sponsor.

NCT07414498 — MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery · NA · not yet recruiting
NCT06999174 — Multiparametric MRI for Characterization of Hepatocellular Carcinoma · recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06648733 — Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care · NA · recruiting
NCT06464302 — Investigation of the Effect of Age and Injury Severity on Short-term Intra-hospital Outcomes After Surgical Stabilized R · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00204230 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Muenster
Last refreshed: 12 September 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00204230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing